Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-derived exosomal lncRNA SNHG4 promotes triple-negative breast cancer progression by targeting XPO5

ABSTRACT: Tumor-derived exosomal lncRNA SNHG4 promotes triple-negative breast cancer progression by targeting XPO5

PROVIDER: PRJNA1281179 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Tumor-derived exosomal lncRNA SNHG4 promotes triple-negative breast cancer progression by targeting XPO5

Project description:Triple-negative breast cancer (TNBC) is the subtype of advanced breast cancer with the shortest survival time and the poorest prognosis, and treatment options are relatively limited. Exosomes, small extracellular vesicles enriched with bioactive molecules, are critical mediators of intercellular communication and have been implicated in cancer progression. The aim of this study was to investigate the molecular mechanism of exosomes promoting the proliferation and migration of TNBC.

2025-06-24 | GSE300559 | GEO

LncRNA expression profile in triple negative breast cancer (TNBC)

Project description:LncRNA expression profile in triple negative breast cancer (TNBC)

| PRJNA656835 | ENA

Exosomal lncRNA Microarray Profiling

Project description:Exosomal lncRNA Microarray Profiling

| PRJNA1459262 | ENA

Identification of glucose-regulated lncRNAs in triple-negative breast cancer cells

Project description:To comprehensively identify the glucose-regulated lncRNAs, we have employed ArraryStar LncRNA Microarry discovery platform to detect lncRNA expression in glucose-starved and glucose-stimulated triple-negative breast cancer cells. Differentially expressed LncRNAs with statistical significance were identified through Volcano Plot filtering between two groups.

2019-06-03 | GSE106729 | GEO

Identification of LncRNA Expression Signatures for Triple-negative Breast Cancer

Project description:To identify biologically and clinically novel lncRNAs potentially involved in the progression of breast cancer, we profiled the expression of lncRNAs in two stage III triple-negativebreast cancer tissues and their paired adjacent noncancerous tissues by LncRNA Array 3.0 (ArrayStar). Expression of the mostly upregulated lncRNA (BCAR4) from this signature was quantified in the breast caner tissue microarray by RNA In situ Hybridization and bioinformatic analysis of Oncomine database, confirming its correlation with breast cancer metastasis.

2014-12-01 | GSE60689 | GEO

Targeting the UFL1-AKT Cascade Suppresses Triple-Negative Breast Cancer Progression

Project description:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease with limited therapeutic options. While UFL1-mediated UFMylation has been implicated in various diseases, its role in TNBC remains unexplored. In this study, we demonstrate that AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189, Lys276, and Lys297. This modification enhances AKT phosphorylation and activation, promoting tumor growth and chemoresistance in TNBC. In turn, AKT phosphorylates UFL1 at Thr426, establishing a positive feedback loop that sustains high activity of both pro-oncogenic regulators in TNBC. Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression both in vitro and in vivo. Clinically, elevated pT426 UFL1 expression significantly correlates with increased pAKT levels in TNBC specimens. These findings uncover a crucial positive feedback loop between UFL1 and AKT that drives TNBC progression and suggest that targeting the UFL1-AKT axis could offer a promising therapeutic strategy for TNBC and potentially other aggressive cancers characterized by upregulated UFL1 and AKT activation.

2025-11-12 | PXD062168 | Pride

Breast cancer-associated fibroblast-derived exosomal miR-1290 promotes triple-negative breast cancer cell proliferation

Project description:Breast cancer-associated fibroblast-derived exosomal miR-1290 promotes triple-negative breast cancer cell proliferation

| PRJNA1494512 | ENA

Breast cancer-associated fibroblast-derived exosomal miR-1290 promotes triple-negative breast cancer cell proliferation

Project description:Breast cancer is a major cause of cancer-associated mortality in females. Although therapeutic strategies targeting subtype-specific receptors have been developed for various breast cancer subtypes, effective targeted therapies for triple-negative breast cancer (TNBC) are lacking. Recently, the role of the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), in the progression and metastasis of breast cancer, especially TNBC, has attracted increasing attention. However, the role of exosomes secreted by CAFs in TNBC cell proliferation is poorly understood. Thus, in this study, we analyzed exosomes derived from both CAFs and MDA-MB-231 cells and identified exosomal miR-1290 as a key component. When delivered to TNBC cells (BT-549 and Hs578T), exosomal miR-1290 directly suppressed the expression of the putative tumor suppressor TBC1D4, which was accompanied by reduced TSC1 expression and activation of the mTOR pathway. The promotion of TNBC cell growth by miR-1290 through direct targeting of TBC1D4 was validated using 2D culture models, 3D spheroid models, and in vivo xenograft models. Furthermore, we demonstrated that treatment with the mTOR inhibitor rapamycin and the FDA-approved rapamycin analog everolimus effectively suppressed miR-1290-induced TNBC cell proliferation, suggesting a potential therapeutic strategy for TNBC. Moreover, in patient cohorts, elevated levels of circulating miR-1290 significantly distinguished patients with breast cancer from healthy individuals and correlated with poor survival outcomes. Therefore, miR-1290 and its direct target TBC1D4 have potential value in both targeted treatment and diagnosis of TNBC.

2026-07-17 | GSE338456 | GEO

Transcriptome characterization of triple negative breast cancer [Mexico]

Project description:Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. It is well recognize that clinical and molecular heterogeneity of TNBC is driven in part by mRNA and lncRNAs. To stratify TNBCs, we profiled mRNAs and lncRNA in 158 adjuvant TNBC tumors using an Affymetrix microarray platform. Lehmann clustering analysis allowed us to identify TNBC subtypes featuring unique lncRNA expression patterns, disease free and overall survival rates and particular gene ontology enrichments (performed with GSEA algorithm).

2018-08-31 | GSE86946 | GEO

Transcriptome characterization of triple negative breast cancer [Italy]

2018-08-31 | GSE86945 | GEO